BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crosbie EJ, Kitson SJ, Mcalpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet 2022;399:1412-28. [DOI: 10.1016/s0140-6736(22)00323-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei S, Yi T, OuYang Z, Wu J. Association between ABO blood type and type I endometrial cancer: a retrospective study. J Obstet Gynaecol 2023;43:2153026. [PMID: 36606697 DOI: 10.1080/01443615.2022.2153026] [Reference Citation Analysis]
2 Chen J, Luo X, Wang G, Zhang J, Zhang Y. Analysis of m(6)A methylation patterns and tumor microenvironment in endometrial cancer. Gene 2023;852:147052. [PMID: 36395970 DOI: 10.1016/j.gene.2022.147052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vistad I, Bjørge L. Advanced endometrial cancer: New medical treatment options on the horizon. Acta Obstet Gynecol Scand 2023;102:128-9. [PMID: 36721075 DOI: 10.1111/aogs.14499] [Reference Citation Analysis]
4 Duan J, Yi J, Wang Y. Exploitation of a shared genetic signature between obesity and endometrioid endometrial cancer. Front Surg 2023;10. [DOI: 10.3389/fsurg.2023.1097642] [Reference Citation Analysis]
5 Schubert M, Mettler L, Deenadayal Tolani A, Alkatout I. Fertility Preservation in Endometrial Cancer—Treatment and Molecular Aspects. Medicina 2023;59:221. [DOI: 10.3390/medicina59020221] [Reference Citation Analysis]
6 Duan J, Liu C, Yi J, Wang Y. Shared sex hormone metabolism-related gene prognostic index between breast and endometrial cancers. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1126862] [Reference Citation Analysis]
7 Li F, Zhou C, Li S, Wang J, Li M, Mu H. Bioinformatic analysis of differentially expressed profiles of lncRNAs and miRNAs with their related ceRNA network in endometrial cancer. Medicine (Baltimore) 2023;102:e32573. [PMID: 36701720 DOI: 10.1097/MD.0000000000032573] [Reference Citation Analysis]
8 Wei H, Pan N, Zhang W, Xiong G, Guo W, Dong Z, Ma C. Levonorgestrel-releasing intrauterine system-based therapies for early-stage endometrial cancer: a systematic review and meta-analysis. J Gynecol Oncol 2023. [PMID: 36731895 DOI: 10.3802/jgo.2023.34.e36] [Reference Citation Analysis]
9 Georgiou D, Monje-Garcia L, Miles T, Monahan K, Ryan NAJ. A Focused Clinical Review of Lynch Syndrome. Cancer Manag Res 2023;15:67-85. [PMID: 36699114 DOI: 10.2147/CMAR.S283668] [Reference Citation Analysis]
10 Lv N, Shen S, Chen Q, Tong J. Long noncoding RNAs: glycolysis regulators in gynaecologic cancers. Cancer Cell Int 2023;23:4. [PMID: 36639695 DOI: 10.1186/s12935-023-02849-2] [Reference Citation Analysis]
11 Zhang M, Li R, Zhang S, Wang Y, Zhang J, Guo Y. High expression of CXCL9 gene promotes immune invasion and improves the prognosis of patients with endometrial cancer.. [DOI: 10.21203/rs.3.rs-2348096/v1] [Reference Citation Analysis]
12 Li Y, Zhu C, Xie H, Chen Y, Lv W, Xie X, Wang X. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT). J Gynecol Oncol 2023. [PMID: 36659832 DOI: 10.3802/jgo.2023.34.e37] [Reference Citation Analysis]
13 Ajabnoor G, Alsubhi F, Shinawi T, Habhab W, Albaqami WF, Alqahtani HS, Nasief H, Bondagji N, Elango R, Shaik NA, Banaganapalli B. Computational approaches for discovering significant microRNAs, microRNA-mRNA regulatory pathways, and therapeutic protein targets in endometrial cancer. Front Genet 2022;13:1105173. [PMID: 36704357 DOI: 10.3389/fgene.2022.1105173] [Reference Citation Analysis]
14 Cao SY, Fan Y, Zhang YF, Ruan JY, Mu Y, Li JK. Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis. BMC Cancer 2023;23:31. [PMID: 36624407 DOI: 10.1186/s12885-022-10482-x] [Reference Citation Analysis]
15 Cai X, Zhang Z, Dong Y, Hao T, Yi L, Yang X. A biotin-guided near-infrared fluorescent probe for imaging hydrogen sulfide and differentiating cancer cells. Org Biomol Chem 2023;21:332-8. [PMID: 36533549 DOI: 10.1039/d2ob02034c] [Reference Citation Analysis]
16 Gullo G, Cucinella G, Chiantera V, Dellino M, Cascardi E, Török P, Herman T, Garzon S, Uccella S, Laganà AS. Fertility-Sparing Strategies for Early-Stage Endometrial Cancer: Stepping towards Precision Medicine Based on the Molecular Fingerprint. Int J Mol Sci 2023;24. [PMID: 36614253 DOI: 10.3390/ijms24010811] [Reference Citation Analysis]
17 Xholli A, Londero AP, Jakimovska M, Zermano S, Puma L, Pasqual EM, Kobal B, Cagnacci A. An implementation of the learning curve cumulative summation test to evaluate a practicum for endometrial cancer ultrasound staging. Ultrasonography 2023;42:147-53. [PMID: 36414247 DOI: 10.14366/usg.22078] [Reference Citation Analysis]
18 Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, Liu YS, Zheng G, Zhao JQ, Wei YF, Guo JY, Liu FH, Chang Q, Zhang YX, Liu CG, Zhao YH. The sirtuin family in health and disease. Signal Transduct Target Ther 2022;7:402. [PMID: 36581622 DOI: 10.1038/s41392-022-01257-8] [Reference Citation Analysis]
19 Min Y, Zhang Z. Hysterectomy or/and lymphadenectomy for the survival of patients with primary endometrial cancer: a cohort study using the SEER database. Biotechnol Genet Eng Rev 2022;:1-19. [PMID: 36576245 DOI: 10.1080/02648725.2022.2162235] [Reference Citation Analysis]
20 Wang J, Xu P, Zou G, Yin M, Mao X, Zhang X. ROMA Index Is an Effective Predictor for Advanced Endometrial Cancer before Surgery. Dis Markers 2022;2022:7409368. [PMID: 36590753 DOI: 10.1155/2022/7409368] [Reference Citation Analysis]
21 RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer 2022:ijgc-2022-004039. [PMID: 36600534 DOI: 10.1136/ijgc-2022-004039] [Reference Citation Analysis]
22 Barrett JE, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, Mould T, MacDonald N, Doufekas K, Newton C, Crosbie EJ, Bjørge L, Colombo N, Dostalek L, Costas L, Peremiquel-Trillas P, Ponce J, Matias-Guiu X, Zikan M, Cibula D, Wang J, Sundström K, Dillner J, Widschwendter M. The WID-EC test for the detection and risk prediction of endometrial cancer. Int J Cancer 2022. [PMID: 36533702 DOI: 10.1002/ijc.34406] [Reference Citation Analysis]
23 Li X, Marcus D, Russell J, Aboagye EO, Ellis LB, Sheeka A, Park WE, Bharwani N, Ghaem‐maghami S, Rockall AG. An Integrated Clinical‐MR Radiomics Model to Estimate Survival Time in Patients With Endometrial Cancer. Magnetic Resonance Imaging 2022. [DOI: 10.1002/jmri.28544] [Reference Citation Analysis]
24 Yuan Cheng, Zhongyu Wang, Xiaoxuan Jia, Rong Zhou, Jianliu Wang. Association Between Abdominal Adipose Tissue Distribution and Risk of Endometrial Cancer: A Case-Control Study. Clin Med Insights Oncol 2022;16:11795549221140776. [ DOI: 10.1177/11795549221140776] [Reference Citation Analysis]
25 Oderkerk TJ, van de Kar MRD, Cornel KMC, Bongers MY, Geomini PMAJ. Endometrial cancer after endometrial ablation: a systematic review. Int J Gynecol Cancer 2022;32:1555-60. [PMID: 36375895 DOI: 10.1136/ijgc-2022-003866] [Reference Citation Analysis]
26 Łaniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, Chase DM, Roe DJ, Herbst-Kralovetz MM. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. Biomark Res 2022;10:88. [PMID: 36461062 DOI: 10.1186/s40364-022-00438-5] [Reference Citation Analysis]
27 Lv Y, Xu L. Tamoxifen Regulates Epithelial–Mesenchymal Transition in Endometrial Cancer <i>via</i> the CANP10/NRP1 Signaling Pathway. Biological & Pharmaceutical Bulletin 2022;45:1818-1824. [DOI: 10.1248/bpb.b22-00530] [Reference Citation Analysis]
28 Londero AP, Xholli A, Bertozzi S, Orsaria M, Paudice M, Mariuzzi L, Cagnacci A. Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data. Curr Oncol 2022;29:9215-23. [PMID: 36547135 DOI: 10.3390/curroncol29120721] [Reference Citation Analysis]
29 Liu B, Dong C, Chen Q, Fan Z, Zhang Y, Wu Y, Cui T, Liu F. Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions. Front Oncol 2022;12:1031802. [PMID: 36505874 DOI: 10.3389/fonc.2022.1031802] [Reference Citation Analysis]
30 Roškar L, Pušić M, Roškar I, Kokol M, Pirš B, Smrkolj Š, Rižner TL. Models including preoperative plasma levels of angiogenic factors, leptin and IL-8 as potential biomarkers of endometrial cancer. Front Oncol 2022;12:972131. [PMID: 36505829 DOI: 10.3389/fonc.2022.972131] [Reference Citation Analysis]
31 Sheng S, Liu W, Xue Y, Pan Z, Zhao L, Wang F, Qi X. Follicle-Stimulating Hormone Promotes the Development of Endometrial Cancer In Vitro and In Vivo. Int J Environ Res Public Health 2022;19. [PMID: 36430063 DOI: 10.3390/ijerph192215344] [Reference Citation Analysis]
32 Alessandro L, Low KE, Abushelaibi A, Lim SE, Cheng WH, Chang SK, Lai KS, Sum YW, Maran S. Identification of NRAS Diagnostic Biomarkers and Drug Targets for Endometrial Cancer-An Integrated in Silico Approach. Int J Mol Sci 2022;23. [PMID: 36430761 DOI: 10.3390/ijms232214285] [Reference Citation Analysis]
33 Barr CE, Njoku K, Jones ER, Crosbie EJ. Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features. Diagnostics (Basel) 2022;12. [PMID: 36428894 DOI: 10.3390/diagnostics12112834] [Reference Citation Analysis]
34 Zhao J, Zou J, Jiao W, Lin L, Wang J, Lin Z. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis. Sci Rep 2022;12:18813. [PMID: 36335189 DOI: 10.1038/s41598-022-22879-6] [Reference Citation Analysis]
35 Wang P, Yang S, Liu C, Chang W, Lee F, Lee W. Endometrial cancer: Part I. Basic concept. Taiwanese Journal of Obstetrics and Gynecology 2022;61:951-959. [DOI: 10.1016/j.tjog.2022.09.001] [Reference Citation Analysis]
36 Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, Tanimoto S, Taguchi A, Fukuda T, Miyamoto Y, Tanikawa M, Mori-uchino M, Tsuruga T, Iriyama T, Matsumoto Y, Nagasaka K, Wada-hiraike O, Oda K, Hamamoto R, Osuga Y. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells. Cancers 2022;14:5367. [DOI: 10.3390/cancers14215367] [Reference Citation Analysis]
37 Cui P, Cong X, Zhang Y, Zhang H, Liu Z. Endometrial clear cell carcinoma: A population-based study. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.961155] [Reference Citation Analysis]
38 Jiang X, Song J, Zhang A, Cheng W, Duan S, Liu X, Chen T. Preoperative Assessment of MRI-Invisible Early-Stage Endometrial Cancer With MRI-Based Radiomics Analysis. J Magn Reson Imaging 2022. [PMID: 36259352 DOI: 10.1002/jmri.28492] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Liu Z, Yang H, Chen Z, Jing C. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. Hereditas 2022;159:40. [PMID: 36253800 DOI: 10.1186/s41065-022-00253-w] [Reference Citation Analysis]
40 Yan G, Li Y, Du Y, Ma X, Xie Y, Zeng X. Survival nomogram for endometrial cancer with lung metastasis: A SEER database analysis. Front Oncol 2022;12:978140. [DOI: 10.3389/fonc.2022.978140] [Reference Citation Analysis]
41 Wan A, Zhao W, Tao J. Causal effects of systemic lupus erythematosus on endometrial cancer: A univariable and multivariable Mendelian randomization study. Front Oncol 2022;12:930243. [DOI: 10.3389/fonc.2022.930243] [Reference Citation Analysis]
42 Miao M, Miao Y, Zhu Y, Wang J, Zhou H. Advances in Exosomes as Diagnostic and Therapeutic Biomarkers for Gynaecological Malignancies. Cancers 2022;14:4743. [DOI: 10.3390/cancers14194743] [Reference Citation Analysis]
43 Cagnacci A, Londero AP. Hormone therapy in endometrial cancer survivors: time for a change. Gynecol Endocrinol 2022;:1-2. [PMID: 36170886 DOI: 10.1080/09513590.2022.2128105] [Reference Citation Analysis]
44 Otsuka I. Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy. Cancers (Basel) 2022;14:4516. [PMID: 36139675 DOI: 10.3390/cancers14184516] [Reference Citation Analysis]
45 Jin X, Zhang H, Wang J, Li J, Zhong Y, Cao X, Jin J, Lin Y, Ma X, Yu Z, Ni X, Li X, Lin M, He J, Luo X, Gu C, Yang W, Ye M. FBXO7, a tumor suppressor in endometrial carcinoma, suppresses INF2-associated mitochondrial division.. [DOI: 10.21203/rs.3.rs-2032067/v1] [Reference Citation Analysis]
46 Uno K, Yoshihara M, Tano S, Takeda T, Kishigami Y, Oguchi H. Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report. BMC Women's Health 2022;22:375. [DOI: 10.1186/s12905-022-01961-1] [Reference Citation Analysis]
47 Cao S, Fan Y, Zhang Y, Ruan J, Mu Y, Li J. Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2002220/v1] [Reference Citation Analysis]
48 Yang S, Dai W, Wang J, Zhang X, Zheng Y, Bi S, Pang L, Ren T, Yang Y, Sun Y, Zheng Z, Wu S, Kong J. Osthole: An up-to-date review of its anticancer potential and mechanisms of action. Front Pharmacol 2022;13:945627. [DOI: 10.3389/fphar.2022.945627] [Reference Citation Analysis]
49 Shui C, Ran L, Tian Y, Qin L, Gu X, Xu H, Hu C, Zhang L, Xu Y, Cheng C, Huan W. Survival after laparoscopy versus laparotomy for apparent early-stage uterine clear cell carcinoma: Results of a large multicenter cohort study. Front Oncol 2022;12:975485. [DOI: 10.3389/fonc.2022.975485] [Reference Citation Analysis]
50 Fan Y, Li X, Sun H, Gao Z, Zhu Z, Yuan K. Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential. Biomolecules 2022;12:1224. [PMID: 36139062 DOI: 10.3390/biom12091224] [Reference Citation Analysis]
51 Kitson SJ, Aurangzeb O, Parvaiz J, Lophatananon A, Muir KR, Crosbie EJ. Quantifying the Effect of Physical Activity on Endometrial Cancer Risk. Cancer Prev Res (Phila) 2022;15:605-21. [PMID: 35696722 DOI: 10.1158/1940-6207.CAPR-22-0129] [Reference Citation Analysis]
52 Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J, Chen H, Zhao X, Yang L, Lu H. PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies. Front Pharmacol 2022;13:967633. [DOI: 10.3389/fphar.2022.967633] [Reference Citation Analysis]
53 Wei L, Ma X, Hou Y, Zhao T, Sun R, Qiu C, Liu Y, Qiu Z, Jiang J. YAP/TAZ reverse progestin resistance through PI3K-Akt pathway in endometrial carcinoma.. [DOI: 10.21203/rs.3.rs-1922836/v1] [Reference Citation Analysis]
54 Njoku K, Barr CE, Ramchander NC, Crosbie EJ. Impact of pre-treatment prognostic nutritional index and the haemoglobin, albumin, lymphocyte and platelet (HALP) score on endometrial cancer survival: A prospective database analysis. PLoS ONE 2022;17:e0272232. [DOI: 10.1371/journal.pone.0272232] [Reference Citation Analysis]
55 Gu C, Lin C, Zhu Z, Hu L, Wang F, Wang X, Ruan J, Zhao X, Huang S. The IFN-γ-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma. Front Oncol 2022;12:955979. [DOI: 10.3389/fonc.2022.955979] [Reference Citation Analysis]
56 Njoku K, Barr CE, Sutton CJJ, Crosbie EJ. Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer. Cancers 2022;14:3306. [DOI: 10.3390/cancers14143306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Xu T, Ding H, Chen J, Lei J, Zhao M, Ji B, Chen Y, Qin S, Gao Q. Research Progress of DNA Methylation in Endometrial Cancer. Biomolecules 2022;12:938. [DOI: 10.3390/biom12070938] [Reference Citation Analysis]
58 Peremiquel-trillas P, Paytubi S, Pelegrina B, Frias-gomez J, Carmona Á, Martínez JM, de Francisco J, Benavente Y, Barahona M, Briansó F, Canet-hermida J, Caño V, Vidal A, Zanca A, Baixeras N, Rodríguez A, Fernández-gonzalez S, Dueñas N, Càrdenas L, Aytés Á, Bianchi I, Pavón MÀ, Reventós J, Capellà G, Gómez D, Diaz M, Ponce J, Brunet J, Matias-guiu X, Bosch FX, de Sanjosé S, Alemany L, Pineda M, Marin F, Costas L. An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study. JPM 2022;12:1074. [DOI: 10.3390/jpm12071074] [Reference Citation Analysis]
59 Bafligil C, Thompson DJ, Lophatananon A, Ryan NAJ, Smith MJ, Dennis J, Mekli K, O'Mara TA, Evans DG, Crosbie EJ. Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women. Genet Med 2022:S1098-3600(22)00786-9. [PMID: 35704044 DOI: 10.1016/j.gim.2022.05.014] [Reference Citation Analysis]
60 Gao L, Chen G, Liang ZQ, Li JD, Li DM, Tang YL, Tang D, Huang ZG, Chen JH, Luo JY, Zeng JH, Dang YW, Feng ZB. Expression Profile and Molecular Basis of Cyclin-Dependent Kinases Regulatory Subunit 2 in Endometrial Carcinoma Detected by Diversified Methods. Pathol Oncol Res 2022;28:1610307. [PMID: 35693634 DOI: 10.3389/pore.2022.1610307] [Reference Citation Analysis]
61 Jamieson A, Barroilhet LM, Mcalpine JN. Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape. Cancer. [DOI: 10.1002/cncr.34328] [Reference Citation Analysis]
62 Njoku K, Agnew HJ, Crosbie EJ. Impact of Type 2 Diabetes Mellitus on Endometrial Cancer Survival: A Prospective Database Analysis. Front Oncol 2022;12:899262. [DOI: 10.3389/fonc.2022.899262] [Reference Citation Analysis]